By Colin Kellaher

 

Merck & Co. (MRK) on Monday said the U.S. Food and Drug Administration approved its cancer drug Keytruda in combination with Pfizer Inc.'s (PFE) Inlyta for the first-line treatment of patients with advanced renal cell carcinoma, the most common type of kidney cancer.

The Kenilworth, N.J., drug maker said the approval is based on findings from a phase 3 study that showed significant improvements in overall survival, progression-free survival and objective response rate for the combination compared to sunitinib, a chemotherapy drug marketed by Pfizer as Sutent.

Merck said the approval marks the first indication in advanced renal cell carcinoma for Keytruda, a cancer drug that harnesses a patient's immune systems to fight tumors.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

April 22, 2019 07:16 ET (11:16 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024 Click aqui para mais gráficos Pfizer.
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024 Click aqui para mais gráficos Pfizer.